undamentalytics Newsletter
Sign in

Aurinia Pharmaceuticals Inc. income statement

In fiscal 2025, Aurinia Pharmaceuticals Inc. reported revenue of $283m, up 20.4% on the year before, operating income of $105m (a 37.1% margin) and net income of $287m, or $2.07 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue00005046134176235283322
Cost of revenue———001614283330
Gross profit———05045128161207250292
Research and development——415350514550213348
Selling, general and administrative———2297174196195———
General and administrative——14—————17210299
Operating income−25−47−55−91−104−181−111−92−5105156
Interest expense—————003544
Income before tax——−53−88−103−180−106−777114167
Income tax——00−01212−173−147
Net income−23−71−53−88−103−181−108−786287314
Diluted EPS——−$0.63−$0.95−$0.87−$1.40−$0.76−$0.54$0.04$2.07$2.31
Diluted shares (average)35m77m85m93m118m129m142m143m146m139m136m
EBITDA——−55−91−103−178−109−8015124176

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AUPH vs IOVAARVN vs AUPHADPT vs AUPH

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Aurinia Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aurinia Pharmaceuticals Inc.